Abstract
Introduction: This study analyzes the value of PSA kinetics, PSA speed (vPSA), and PSA doubling time (PSAdt), in patients with low-risk prostate cancer who are in an active surveillance (AS) program. Methods: An observational, retrospective, and longitudinal study of a sample of 86 patients included in AS program between January 2014 and October 2021 was conducted. A review of their medical records was performed, and PSA kinetics were calculated, analyzing the causes of discontinuation of the AS program and its relationship with PSA kinetics. Results: The mean age was 63.39 years, and the median follow-up was 62.55 months. The mean PSA at diagnosis was 8.27 ng/mL. A median of PSAdt of 62.55 months and 1.3 ng/mL/year for vPSA was obtained. 35 patients left the program, with a higher percentage of patients leaving with a PSAdt less than 36 months (73.7 vs. 31.1%) and a vPSA greater than 2 ng/mL/year (68.2 vs. 31.3%). The probability of permanence and the time of permanence in AS were statistically significantly higher for those patients with favorable kinetic parameters. Conclusion: PSA kinetics is a parameter to take into account when making decisions to keep patients in an AS program.
Journal Section:
Research Article
References
1.
Shill
DK
, Roobol
MJ
, Ehdaie
B
, Vickers
AJ
, Carlsson
SV
. Active surveillance for prostate cancer
. Transl Androl Urol
. 2021
;10
(6
):2809
–19
.2.
Litwin
MS
, Tan
HJ
. The diagnosis and treatment of prostate cancer. A review
. JAMA
. 2017
;317
(24
):2532
–42
.3.
Celma Domènech
A
, Planas Morin
J
, Morote Robles
J
. Optimización del seguimiento de cáncer de próstata en vigilancia activa
. Arch Esp Urol
. 2014
;67
(5
):442
–51
.4.
Rubio-Briones
J
, Borque
A
, Esteban
LM
, Iborra
I
, López
PA
, Gil
JM
. Preliminary results of the Spanish association of Urology national registry in active surveillance for prostate cancer
. Actas Urol Esp
. 2016
;40
(1
):3
–10
.5.
van den Bergh
RCN
, Roemeling
S
, Roobol
MJ
, Wolters
T
, Schröder
FH
, Bangma
CH
. Prostate-specific antigen kinetics in clinical decision- making during active surveillance for early prostate cancer- A review
. Eur Urol
. 2008
;54
(3
):505
–16
.6.
Thomsen
FB
, Brasso
K
, Berg
KD
, Gerds
TA
, Johansson
JE
, Angelsen
A
. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study
. Ann Oncol
. 2016
;27
(3
):460
–6
.7.
Mottet
N
, van den Bergh
RCN
, Briers
E
, Van den Broeck
T
, Cumberbatch
MG
, De Santis
M
. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
. Eur Urol
. 2021
;79
(2
):243
–62
.8.
Cooperberg
MR
, Brooks
JD
, Faino
AV
, Newcomb
LF
, Kearns
JT
, Carroll
PR
. Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes
. Eur Urol
. 2018
;74
(2
):211
–7
.9.
Pastor-Navarro
B
, Rubio-Briones
J
, Borque-Fernando
Á
, Esteban
LM
, Domínguez-Escrig
JL
, López-Guerrero
JA
. Active surveillance in prostate cancer: role of available biomarkers in daily practice
. Int J Mol Sci
. 2021
;22
(12
):6266
.10.
van den Bergh
RCN
, Roemeling
S
, Roobol
MJ
, Roobol
W
, Schröder
FH
, Bangma
CH
. Prospective validation of active surveillance in prostate cancer: the PRIAS Study
. Eur Urol
. 2007
;52
(6
):1560
–3
.11.
Rubio Briones
J
, Iborra
I
, Ramírez
M
, Calatrava
A
, Collado
A
, Casanova
J
. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know
. Actas Urol Esp
. 2014
;38
(9
):559
–65
.12.
Pound
CR
, Partin
AW
, Eisenberger
MA
, Chan
DW
, Pearson
JD
, Walsh
PC
. Natural history of progression after PSA elevation following radical prostatectomy
. JAMA
. 1999
;281
(17
):1591
–7
.13.
Song
SH
, Kim
JK
, Lee
H
, Lee
S
, Hong
SK
, Byun
SS
. A single-center long-term experience of active surveillance for prostate cancer:15 years of follow-up
. Investig Clin Urol
. 2021
;62
(1
):32
–8
.14.
Hamdy
FC
, Donovan
JL
, Lane
JA
, Mason
M
, Metcalfe
C
, Holding
P
. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer
. N Engl J Med
. 2016
;375
(15
):1415
–24
.15.
Rajwa
P
, Pradere
B
, Quhal
F
, Mori
K
, Laukhtina
E
, Huebner
NA
. Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis
. Eur Urol
. 2021
;80
(5
):549
–63
.16.
Carter
HB
, Pearson
JD
, Metter
EJ
, Brant
LJ
, Chan
DW
, Andres
R
. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
. JAMA
. 1992
;267
(16
):2215
–20
.17.
Rubio Briones
J
, Pastor Navarro
B
, Esteban Escaño
LM
, Borque Fernando
A
. Update and optimization of active surveillance in prostate cancer in 2021
. Actas Urol Esp
. 2021
;45
:1
–7
.18.
Newcomb
LF
, Thompson
IM
, Boyer
HD
, Brooks
JD
, Carroll
PR
, Cooperberg
MR
. Outcomes of active surveillance for clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort
. J Urol
. 2016
;195
(2
):313
–20
.19.
Klotz
L
, Vesprini
D
, Sethukavalan
P
, Jethava
V
, Zhang
L
, Jain
S
. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
. J Clin Oncol
. 2015
;33
(3
):272
–7
.20.
Ng
MK
, Van As
N
, Thomas
K
, Woode-Amissah
R
, Horwich
A
. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time
. BJU Int
. 2009
;103
(7
):872
–6
.21.
Ross
PL
, Mahmud
S
, Stephenson
AJ
, Souhami
L
, Tanguay
S
, Aprikian
AG
. Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: value of short-term PSADT determinations
. Urology
. 2004
;64
(2
):323
–8
.22.
Carter
HB
, Morrell
CH
, Pearson
J
, Brant
LJ
, Plato
CC
, Metter
EJ
. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
. Cancer Res
. 1992
;52
(12
):3323
–8
.23.
Balakrishnan
AS
, Cowan
JE
, Cooperberg
MR
, Shinohara
K
, Nguyen
HG
, Carroll
PR
. Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance
. J Urol
. 2019
;202
(3
):506
–10
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
